Results

Total Results: 1,636 records

Showing results for "treating".

21. PEPTIC ULCER #11 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/peptic-ulcer-horizon-scan-high-impact-1506.pdf
    June 01, 2015 - In May 2015, FDA approved eluxadoline under the tradename Viberzi™ for treating diarrhea-predominant … Food and Drug Administration (FDA) for treating diarrhea-predominant IBS. … (Laval, Quebec, Canada), developed rifaximin for treating diarrhea-predominant IBS. … Rifaximin had been previously approved by FDA for treating travelers’ diarrhea caused by E. coli in … IBS with diarrhea in adults.2,8 Per approved labeling, rifaximin dosage for treating IBS is 550 mg

22. #05 DEPRESSION (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/depression-horizon-scan-high-impact-1406.pdf
    June 01, 2014 - (Menlo Park, CA), was investigating it for rebranded use in treating psychotic major depression. … Paul, MN), that targets the subcallosal cingulate gyrus brain region for treating MDD. … Lundbeck a/s (Valby, Denmark), received FDA approval to market the drug for treating MDD. … Scopolamine, a medication FDA previously approved for treating peptic ulcers, motion sickness, and … Glutamatergic modulators: the future of treating mood disorders?

23. Preventing Complications and Treating Symptoms of Diabetic Peripheral Neuropathy | Effective Health Care (EHC) Program
    effectivehealthcare.ahrq.gov/products/diabetic-neuropathy

24. #06 Developmental Delays ADHD, and Autism (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/developmental-delays-horizon-scan-high-impact-1506.pdf
    December 01, 2015 - have demonstrated promising efficacy and are under investigation in late-stage clinical trials for treating … extended release formulation of metadoxine, an ion-pair salt widely prescribed internationally for treating … late 2014, investigators reported top-line results from a phase III study examining metadoxine for treating … adult ADHD; a similar trial is also planned to study this drug for treating pediatric ADHD. … pediatric ADHD and a phase III trial for treating adult ADHD; each of these studies is scheduled to

25. Arthritis and Nontraumatic Joint Disease (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/arthritis-horizon-scan-high-impact-1512.pdf
    December 29, 2015 - (RA), an oral drug for treating gout, and a monoclonal antibody for treating either ankylosing spondylitis … Five phase III trials are ongoing of secukinumab for treating AS. … AS, as well as for treating PsA. … If approved for treating AS, secukinumab would likely be covered by third- party payers for treating … Five phase III trials on secukinumab for treating PsA are ongoing.

26. Layout 1 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/antidepressants-update_executive.pdf
    December 01, 2011 - a patient has responded to one agent in the past, is that agent better than current alternatives at treating … of medications (including tricyclics in combination) differ in their efficacy or effectiveness for treating … the depressive episode or for treating the accompanying symptoms? … The same study found that sertraline was more efficacious than fluoxetine for treating depression in … Low Energy One placebo-controlled RCT showed that bupropion XR is superior to placebo for treating low

27. #05 DEPRESSION (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/depression-horizon-scan-high-impact-1312.pdf
    October 01, 2014 - It can be prescribed off label for treating PMD. … DBS, a ES-4 standard modality for treating some movement disorders (e.g., essential tremor, … Paul, MN) are in phase III development for DBS for treating BPD and MDD. … One expert with clinical experience treating this patient population stated that treating PMD has been … Glutamatergic modulators: the future of treating mood disorders?.

28. #05 DEPRESSION (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/depression-horizon-scan-high-impact-1306.pdf
    October 01, 2014 - A second approach, the proposed use of an implanted deep brain stimulator for treating depression, … For this condition, no FDA-approved interventions are available, and treating this population remains … Paul, MN) are in phase III development for DBS for treating MDD. … One expert with clinical experience treating this patient population stated that treating PMD has been … Glutamatergic modulators: the future of treating mood disorders?

29. Update Topic CER 31 Clostridium difficile NSD FINAL (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/c-diff-infections-nomination-140925.pdf
    February 19, 2014 - § Treating CDI, active control § Treating CDI, placebo § Treating recurrent CDI § Preventing CDI

30. #05 DEPRESSION (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/depression-horizon-scan-high-impact-1512.pdf
    December 01, 2015 - and colleagues in PLoS One implies that behavioral therapies may be up to 25% less effective for treating … indications and in case studies was also effective for treating military patients deployed in combat … Intervention: Telemedicine-facilitated psychotherapy for treating PTSD encompasses any psychotherapy … for treating PTSD.87-92 We have organized the following discussion of expert comments by the parameters … Glutamatergic modulators: the future of treating mood disorders?

31. Psychosocial and Pharmacologic Interventions for Disruptive Behavior Disorders in Children and Adolescents: Current State of the Evidence (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/disruptive-behavior-disorder_clinician.pdf
    August 01, 2016 - Conventional approaches to treating children with DBDs include psychosocial and pharmacologic interventions … www.mstservices.com/ Table 1: Summary of Evidence on the Effectiveness of Psychosocial Interventions in Treating … strength of evidence Table 2: Summary of Evidence on the Effectiveness of Pharmacologic Interventions in Treating … studies of pharmacologic interventions were frequently used without a research basis for their use in treating … No. 15(16)-EHC019-3-EF August 2016 www.ahrq.gov Companion Resource for Parents and Caregivers Treating

32. DEMENTIA INCLUDING ALZHEIMER'S #04 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/dementia-horizon-scan-high-impact-1406.pdf
    February 01, 2015 - The Horizon Scanning System continues to track several interventions and diagnostics for treating dementia … Research into intranasal insulin’s efficacy for treating AD is being advanced by several academic and … In the absence of more clinical evidence for treating AD, off-label insulin use may be relatively limited … Food and Drug Administration (FDA) for treating diabetes, including Humulin® and Humulin R® (Eli Lilly … cognitive symptoms of AD.13 Diffusion and cost: Intranasal insulin for treating AD is not sold in

33. #05 DEPRESSION (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/depression-horizon-scan-high-impact-1412.pdf
    December 01, 2014 - Some clinical practices report offering ketamine infusions for treating depression; patient blogs also … Scopolamine is an anticholinergic agent, FDA-approved for treating peptic ulcers, motion sickness, … depression indications.12 In clinical trials for treating MDD and BPD, investigators intravenously … Ketamine is not approved for treating BPD or MDD, and no manufacturers are sponsoring clinical trials … Glutamatergic modulators: the future of treating mood disorders?

34. #05 DEPRESSION (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/05_depression_potential_high_impact_2012-12-10.pdf
    January 01, 2012 - The proposed use of implanted devices for treating mental health conditions represents a departure … For this condition, no interventions are specifically approved by FDA, and treating this population … Mifepristone for treating PMD is being investigated in one phase III clinical trial. … One expert, with clinical experience in treating this patient population stated that treating PMD has … Glutamatergic modulators: the future of treating mood disorders?

35. Obesity (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/obesity-horizon-scan-high-impact-1412.pdf
    December 01, 2014 - In September 2011, concerns over the lack of effective pharmacotherapies for treating obesity drove … obesity while the company pursues a labeled indication for treating obesity. … addiction and approved in 1994 for treating alcohol dependence. … They saw no potential for high impact in terms of treating obesity. … Maestro has been CE marked since 2009 for treating obesity.

36. #06 Developmental Delays ADHD, and Autism (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/developmental-delays-horizon-scan-high-impact-1406.pdf
    June 01, 2014 - Several academic centers are investigating off-label, intranasal oxytocin for treating social cognitive … manufacturers and sold as an injectable solution.38,39 Clinical trials investigating oxytocin for treating … Stanford University School of Medicine, Stanford, CA—are investigating intranasal oxytocin for treating … In 2006, FDA approved risperidone for treating irritability in children with a diagnosis of autism. … cognition and associated behaviors.45 Patients who have been given intranasal oxytocin spray for treating

37. Effective Health Care (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/TND_0012_03-21-2008.pdf
    January 01, 2008 - professional association Nomination Summary: The nominator is interested in the benefits and harms of treating … What are the benefits and harms of treating patients with subclinical hypothyroidism vs. watchful waiting

38. #06 Developmental Delays ADHD, and Autism (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/developmental-delays-horizon-scan-high-impact-1312.pdf
    December 01, 2013 - However, no effective pharmacologic treatments exist for treating social deficits in individuals with … Several academic medical centers are investigating off-label, intranasal oxytocin for treating social … A common dosage used in ongoing clinical trials for treating ASD-related social dysfunction is 24 IU … they acknowledged the great potential for intranasal oxytocin to become the standard of care for treating … In 2006, FDA approved risperidone (Risperdal®) for treating irritability in autistic children and in

39. DEMENTIA INCLUDING ALZHEIMER'S #04 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/dementia-horizon-scan-high-impact-1312.pdf
    December 01, 2013 - In this report, we discuss the off-label use of insulin for treating AD. … Because insulin is not approved for treating AD and no particular company appears to be pursuing trials … to secure FDA approval for a labeled indication for AD, its use for treating AD is considered to be … Study registered the largest randomized, controlled trial to date (n=240) for this intervention for treating … been administered using a variety of intranasal administration devices; insulin products tested for treating

40. Horizon Scanning_Rapid Cost Analyses of Selected Potential High-Impact Intervention Reports (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/horizon-scan_research-2015.pdf
    January 01, 2015 - Of interest is that new drugs for treating one disease—direct-acting oral antivirals, which provide … For example, we estimated that treating all chronic HCV-infected patients who are candidates for one … In December 2014, an injected drug long used for treating type 2 diabetes received FDA approval for … We estimated that the adoption of enzalutamide for treating metastatic castration-resistant prostate … We estimate the annual cost of treating 316 adults at about $110 million.